Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy

Author(s): Latov N, Deng C, Dalakas MC, Bril V, Donofrio P, et al.

Abstract

Objective:To investigate the timing, course, and clinical characteristics of the response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy (CIDP).

Design:Data were extracted from the ICE trial, a randomized, double-blind, placebo-controlled trial of immune globulin intravenous, 10% caprylate/chromatography purified (IGIV-C).

Setting:Multiple international centers.

Participants:One hundred seventeen individuals with CIDP. Intervention Treatment with IGIV-C (Gamunex, n = 59) or placebo (n = 58), with IGIV-C administered as a 2-g/kg loading dose followed by a 1-g/kg maintenance dose every 3 weeks, for up to 24 weeks.

Main outcome measures:The primary efficacy parameter was an improvement of 1 or more points in adjusted Inflammatory Neuropathy Cause and Treatment (INCAT) disability score. Participants treated with IGIV-C were divided into subgroups based on meeting responder vs nonresponder definitions and by time to first improvement.

Results:Among 30 responders to IGIV-C, 14 (47%) patients had improved adjusted INCAT scores by week 3, and 16 (53%) patients improved at week 6 after a second infusion. Participants who improved by week 3 were more severely disabled at baseline than those who improved at 6 weeks. In patients who improved, the number of individuals reaching maximal improvement continued to increase during maintenance therapy for up to 24 weeks. For patients with first improvement by week 3, the change in dominant-hand grip strength over time tended to parallel the INCAT score. In patients with first improvement by week 6, however, the improvement in dominant-hand grip strength preceded initial improvement in INCAT score.

Conclusions:Data suggest that treatment with 2 courses of IGIV-C administered 3 weeks apart may be required for initial improvement, and continued maintenance therapy may be necessary to achieve a maximal therapeutic response. Trial Registration clinicaltrials.gov Identifier: NCT00220740.

Similar Articles

Safety of intravenous immunoglobulin (IVIG) therapy

Author(s): Katz U, Achiron A, Sherer Y, Shoenfeld Y

Intravenous immunoglobulin: adverse effects and safe administration

Author(s): Orbach H, Katz U, Sherer Y, Shoenfeld Y

Complications of intravenous immune globulin treatment in neurologic disease

Author(s): Brannagan TH 3rd, Nagle KJ, Lange DJ, Rowland LP

Adverse effect of polyvalent immunoglobulin in the treatment of Guillain-Barre syndrome

Author(s): Chamouni P, Tamion F, Gueit I, Girault C, Lenain P, et al.

Patient demographics and health plan paid costs in chronic inflammatory demyelinating polyneuropathy

Author(s): Guptill JT, Bromberg MB, Zhu L, Sharma BK, Thompson AR, et al.

Diffuse muscular coactivation [DMC] as a potential source of pain in fibromyalgia -- part 1

Author(s): Donaldson CC, Snelling LS, MacInnis AL, Sella GE, Mueller HH

Pregabalin for fibromyalgia: some relief but no cure

Author(s): Kim L, Lipton S, Deodhar A

The effects of pregabalin on sleep disturbance symptoms among individuals with fibromyalgia syndrome

Author(s): Russell IJ, Crofford LJ, Leon T, Cappelleri JC, Bushmakin AG, et al.

The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia

Author(s): Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, et al.

Prevalence and factors associated with fibromyalgia in Mexican patients with systemic lupus erythematosus

Author(s): Valencia-Flores M, Cardiel MH, Santiago V, Resendiz M, Castaño VA, et al.

The prevalence and characteristics of fibromyalgia in the general population

Author(s): Wolfe F, Ross K, Anderson J, Russell IJ, Hebert L

Estimates of the prevalence of arthritis and other rheumatic conditions in the United States

Author(s): Lawrence RC, Felson DT, Helmick CG, Arnold LM, Choi H, et al.

Prevalence of fibromyalgia in children: a clinical study of Mexican children

Author(s): Clark P, Burgos-Vargas R, Medina-Palma C, Lavielle P, Marina FF

Management of fibromyalgia syndrome

Author(s): Goldenberg DL, Burckhardt C, Crofford L

Fibromyalgia syndrome module at OMERACT 9: domain construct

Author(s): Mease P, Arnold LM, Choy EH, Clauw DJ, Crofford LJ, et al.

Toward development of a fibromyalgia responder index and disease activity score: OMERACT module update

Author(s): Mease PJ, Clauw DJ, Christensen R, Crofford LJ, Gendreau RM, et al.

Nerve ultrasound score in distinguishing chronic from acute inflammatory demyelinating polyneuropathy

Author(s): Kerasnoudis A, Pitarokoili K, Behrendt V, Gold R, Yoon MS

Clinical spectrum of chronic acquired demyelinating polyneuropathies

Author(s): Saperstein DS, Katz JS, Amato AA, Barohn RJ

Chronic inflammatory demyelinating polyradiculoneuropathy

Author(s): Barohn RJ, Kissel JT, Warmolts JR, Mendell JR

Chronic inflammatory polyradiculoneuropathy

Author(s): Dyck PJ, Lais AC, Ohta M, Bastron JA, Okazaki H, et al.

Derivation and validation of diagnostic criteria for chronic inflammatory demyelinating polyneuropathy

Author(s): Koski CL, Baumgarten M, Magder LS, Barohn RJ, Goldstein J, et al.

IVIG regulates BAFF expression in patients with chronic inflammatory demyelinating polyneuropathy (CIDP)

Author(s): Ritter C, Förster D, Albrecht P, Hartung HP, Kieseier BC, et al.

Immunosuppressive treatment in refractory chronic inflammatory demyelinating polyradiculoneuropathy

Author(s): Cocito D, Grimaldi S, Paolasso I, Falcone Y, Antonini G, et al.

High prevalence of restless legs syndrome among patients with fibromyalgia: a controlled cross-sectional study

Author(s): Viola-Saltzman M, Watson NF, Bogart A, Goldberg J, Buchwald D